Idogen Running Out Of Survival Options

Swedish Firm Seeking Reverse Merger Solution

02 May 2023

With very little cash left in the bank, Idogen is weighing up its options including a reverse merger or liquidation.

Padlock — Idogen faces closure if reverse merger efforts fail • Source: Shutterstock

The future of Idogen AB hangs in the balance with the Swedish firm's critical financial situation leaving its lead clinical-stage development program IDO 8 for hemophilia in limbo.

Idogen's announcement on 28 April that its "work with capitalization has not yet produced the desired result" is quite an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: MapLight’s Mega-Round Funds Exploration Of Its Cobenfy Competitor

29 Jul 2025

• By Mandy Jackson

Private Company Edition: MapLight raised a $372.5m series D round to fund ongoing Phase II trials and investigation of additional indications for its M1/M4 muscarinic agonist. Also, Scrip spoke with Modi Ventures about its new fund.

Abivax Over The Moon As Obefazimod Storms Phase III

23 Jul 2025

• By Kevin Grogan

Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.

Scrip M&A Podcast: Is Biopharma M&A In A Holding Pattern Or A ‘New Normal’

23 Jul 2025

• By Joseph Haas

Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.

Finance Watch: Sarepta’s Debt Woes Grow With Elevidys Shipment Pause

22 Jul 2025

• By Mandy Jackson

Public Company Edition: Sarepta restructured after stopping shipments of its Elevidys for some patients to ease future debt pressures, but now it has stopped shipments to all patients. Also, Madrigal secured up to $500m in new debt, Cogent closed a $230m offering and other financings.